CD247 and diffuse large B-cell lymphoma: Tisagenlecleucel (KYMRIAH, Novartis), with the 4-1BB/CD3ζ costimulatory domain, was approved in August 2017 for B-ALL (20) and in May 2018 for DLBCL, and axicabtagene ciloleucel (YESCARTA, Kite Pharmaceuticals), with the CD28/CD3ζ costimulatory domain, was approved for DLBCL in October 2017.